The Use of Animal Neuropeptides in the Treatment of ...

References

1. Lau, J. L. and Dunn, M. K., “Therapeutic peptides: Historical perspectives, current development trends, and future directions,” Bioorg. Med. Chem., 26, No. 10, 2700–2707 (2018), https://doi.org/10.1016/j.bmc.2017.06.052.

   Article  CAS  PubMed  Google Scholar 

2. Lee, A. C., Harris, J. L., Khanna, K. K., and Hong, J. H., “A comprehensive review on current advances in peptide drug development and design,” Int. J. Mol. Sci., 20, No. 10, 2383 (2019), https://doi.org/10.3390/ijms20102383.

3. Muttenthaler, M., King, G. F., Adams, D. J., and Alewood, P. F., “Trends in peptide drug discovery,” Nat. Rev. Drug Discov., 20, No. 4, 309–325 (2021), https://doi.org/10.1038/s41573-020-00135-8.

   Article  CAS  PubMed  Google Scholar 

4. Khavinson, V. Kh., “Therapeutic peptide formulations: past, present, future,” Klinich. Med., 98, No. 3, 165–177 (2020), https://doi.org/10.30629/0023-2149-2020-98-3-165-177.

5. Putilina, M. V. “Endothelium as a target for novel therapeutic strategies in vascular brain diseases,” Zh. Nevrol. Psikhiatr., 117, No. 10, 122–130 (2017), https://doi.org/10.17116/jnevro2017117101122-130.

6. Gomazkov, O. A., Functional Biochemistry of Regulatory Peptides, Nauka, Moscow (1993).

   Google Scholar 

7. Nam, S. H., Park, J., and Koo, H., “Recent advances in selective and targeted drug/gene delivery systems using cell-penetrating peptides,” Arch. Pharm. Res., 46, No. 1, 18–34 (2023), https://doi.org/10.1007/s12272-022-01425-y.

   Article  CAS  PubMed  PubMed Central  Google Scholar 

8. Moretta, A., Scieuzo, C., Petrone, A., et al., “Antimicrobial peptides: A new hope in biomedical and pharmaceutical fields,” Front. Cell. Infect. Microbiol., 11, No. 8, 456–462 (2014), https://doi.org/10.3389/fcimb.2021.668632.

   Article  CAS  Google Scholar 

9. Apostolopoulos, V., Bojarska, J., Feehan, J., et al., “Smart therapies against global pandemics: A potential of short peptides,” Front. Pharmacol., 13, 914467 (2025), https://doi.org/10.3389/fphar.2022.914467.

   Article  CAS  Google Scholar 

10. Zhou, X., Smith, Q. R., and Liu, X., “Brain-penetrating peptides and peptide-drug conjugates for overcoming the blood–brain barrier and combating diseases of the central nervous system,” Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 12, No. 34, 1695 (2021), https://doi.org/10.1002/wnan.1695.

11. Zhao, L., Liu, J. W., Shi, H. Y., and Ma, Y. M., “Neural stem cell therapy for brain disease,” World J. Stem Cells, 13, No. 9, 1278–1292 (2021), https://doi.org/10.4252/wjsc.v13.i9.1278.

    Article  PubMed  PubMed Central  Google Scholar 

12. Kulesh, A. A. and Shestakov, V. V., “Poststroke cognitive impairments and the potentials of Cellex therapy,” Zh. Nevrol. Psikhiatr., 116, No. 5, 38–42 (2016), https://doi.org/10.1007/s11055-017-0490-3.

    Article  CAS  Google Scholar 

13. Gromova, O. A., Torshin, I. Yu., and Gogoleva, I. V., “Mechanisms of neurotrophic and neuroprotective actions of Cerebrolysin in cerebral ischemia,” Zh. Nevrol. Psikhiatr., 114, No. 3–2, 43–50 (2014).

    CAS  Google Scholar 

14. Putilina, M. V., “Current concepts of small-vessel brain disease,” Zh. Nevrol. Psikhiatr., 119, No. 11, 65–73 (2019), https://doi.org/10.17116/jnevro201911911165.

15. Bornstein, N. M., Guekht, A., Vester, J., et al., “Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials,” Neurol. Sci., 39, No. 4, 629–640 (2018), https://doi.org/10.1007/s10072-017-3214-0.

    Article  PubMed  Google Scholar 

16. Gavrilova, S. I. and Alvarez, A., “Cerebrolysin in the therapy of mild cognitive impairment and dementia due to Alzheimer’s disease: 30 years of clinical use,” Med. Res. Rev., 45, No. 12, 45–51 (2020), https://doi.org/10.1002/med.21722.

    Article  CAS  Google Scholar 

17. Gomazkov, O. A., “Cortexin: molecular mechanisms and targets of neuroprotective activity,” Zh. Nevrol. Psikhiatr., 115, No. 8, 99–104 (2015), https://doi.org/10.17116/jnevro20151158199-104.

18. Pinelis, V. G., Storozhevykh, T. P., Surin, A. M., et al., “Neuroprotective effects of cortagen, cortexin and semax on glutamate neurotoxicity,” J. Peptide Sci., 14, No. 8, 159–160 (2008).

    Google Scholar 

19. Soudy, R., Kimura, R., and Patel, A., “Short amylin receptor antagonist peptides improve memory deficits in Alzheimer’s disease mouse model,” Sci. Rep., 9, 10942 (2019), https://doi.org/10.1038/s41598-019-47255-9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

20. Yakovlev, A. A. and Gulyaeva, N. V., “Molecular partners of Cortexin in the brain,” Neirokhimiya, 34, No. 1, 91–96 (2017), https://doi.org/10.7868/S1027813316040166.

    Article  Google Scholar 

21. Yakovlev, A. A., Lyzhin, A. A., Khaspekov, L. G., et al., “The peptide-based drug cortexin inhibits brain caspase-8,” Biochemistry (Moscow), Suppl. Series B: Biomed Chem., 11, No. 2, 134–138 (2017), https://doi.org/10.1134/s1990750817020111.

    Article  Google Scholar 

22. Lee, J. and Kim, C., “Peptide materials for smart therapeutic applications,” Macromol. Res., 29, 2–14 (2021), https://doi.org/10.1007/s13233-021-9011-x.

    Article  CAS  Google Scholar 

23. Putilina, M. V., Mutovina, Z. Yu., and Kurushina, O. V., et al., “Determination of the prevalence of post-Covid syndrome and assessment of the efficacy of the drug Cortexin in the treatment of neurological disorders in patients with post-Covid syndrome. Results of the CORTEX multicenter observational program,” Zh. Nevrol. Psikhiat., 122, No. 1, 84–90 (2022), https://doi.org/10.17116/jnevro202212201184.

24. Fedin, A. I., Bel’skaya, G. N., Kurushina, O. V., et al., “Dose-dependent effects of Cortexin in chronic cerebral ischemia (results of a multicenter randomized controlled trial),” Zh. Nevrol. Psikhiatr., 118, No. 9, 35–42 (2018), https://doi.org/10.17116/jnevro201811809135.

25. Putilina, M. V., “Pathogenetic approaches to the therapy of sleep disorders in comorbid patients,” Zh. Nevrol. Psikhiatr., 122, No. 11, 11–16 (2022), https://doi.org/10.17116/jnevro202212211111.

26. Tyurenkov, I. N., Kurkin, D. V., and Kalatanova, A. V., et al., “A comparative study of the effects of Cortexin, Cerebrolysin, and Actovegin on memory, cerebral circulation, and hippocampus structure in rats with chronic cerebrovascular accident,” Zh. Nevrol. Psikhiatr., 120, No. 8, 83–89 (2020), https://doi.org/10.17116/jnevro202012008183.

27. Gromova, O. A., Torshin, I. Yu., Putilina, M. V., et al., “Selection of neuroprotective therapies in patients with chronic cerebral ischemia, taking account of the synergy of drug interactions,” Zh. Nevrol. Psikhiat., 120, No. 8, 42–50 (2020), https://doi.org/10.17116/jnevro202012008142.

28. Putilina, M. V. and Teplova, N. V., “Drug synergy as basis for rational neuroprotection,” Zh. Nevrol. Psikhiatr., 122, No. 5, 17–22 (2022), https://doi.org/10.17116/jnevro202212205117.

29. Lubell, W. D., “Peptide-based drug development,” Biomedicines, 10, No. 8, 2037 (2022), https://doi.org/10.3390/biomedicines10082037.

    Article  Google Scholar 

30. Putilina, M. V., “Combined neuroprotective therapy for cerebrovascular diseases,” Vrach, 4, No. 3, 69–73 (2012).

    Google Scholar 

Download references